Myelodysplastic syndromes--many new drugs, little therapeutic progress.

Item

http://www.wikidata.org/entity/Q42186622

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

2010年论文

@zh

2010年论文

@zh-cn

name

Myelodysplastic syndromes--many new drugs, little therapeutic progress.

@en

Myelodysplastic syndromes--many new drugs, little therapeutic progress.

@nl

type

Item

label

Myelodysplastic syndromes--many new drugs, little therapeutic progress.

@en

Myelodysplastic syndromes--many new drugs, little therapeutic progress.

@nl

prefLabel

Myelodysplastic syndromes--many new drugs, little therapeutic progress.

@en

Myelodysplastic syndromes--many new drugs, little therapeutic progress.

@nl

P1476

Myelodysplastic syndromes--many new drugs, little therapeutic progress.

@en

P2860

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study

International scoring system for evaluating prognosis in myelodysplastic syndromes

Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs.

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.

Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q.

Treatment of transfusional iron overload in patients with myelodysplastic syndrome or severe anemia: data from multicenter clinical practices.

WHO-defined 'myelodysplastic syndrome with isolated del(5q)' in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations.

Transfusion-dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis--prognostic relevance is independent of IPSS or karyotype.

P304

1042-1045

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4065/MCP.2010.0502

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Ayalew Tefferi

P577

2010-09-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

46403496

http://www.w3.org/2001/XMLSchema#string

P698

20861462

http://www.w3.org/2001/XMLSchema#string

P932

2966368

http://www.w3.org/2001/XMLSchema#string